Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells

Pathology Research and Practice

Volumn 206, Issue 4, 2010, Pages 253-258

  Strien, Leena ^a   Leidenius, Marjut ^a   von Smitten, Karl ^a   Heikkilä, Päivi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Breast cancer; Her 2; Isolated tumor cells; Sentinel node metastasis; Steroid hormone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL ISOLATION; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROMETASTASIS; PRIMARY TUMOR; PROTEIN ANALYSIS; SENTINEL LYMPH NODE BIOPSY; TUMOR CELL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL;

EID: 77950859277     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2009.12.006     Document Type: Article

References (45)

1. UICC TNM Classification of Malignant Tumours 2002, 131-141. Wiley, New York. 6th ed. H. Sobin, C. Wittekind (Eds.).
2. Bleiweiss I.J., Nagi C.S., Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J. Clin. Oncol. 2006, 13:2013-2018.
3. Diaz N.M., Cox C.E., Ebert M., et al. Benign mechanical transport of breast epithelial cells to sentinel lymph nodes. Am. J. Surg. Pathol. 2004, 28:1641-1645.
4. Ross J.S., Fletcher J.A. HER-2/neu (c- erbB2) gene and protein in breast cancer. Am. J. Clin. Pathol. 1999, 112:S53-S56.
5. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. NEJM 2005, 16:1659-1672.
6. Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEJM 2006, 8:809-820.
7. Geyer C., Forster J., Lindquist D., Chan S., et al. Lapatinib plus Capecitabine for HER-2-Positive advanced breast cancer. NEJM 2006, 26:2733-2743.
8. Bassarova A.V., Nesland J.M., Sedloev T., et al. Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alfa, high Ki-67 and bcl-2, and low p53. Int. J. Surg. Pathol. 2005, 13:239-246.
9. Tanner M., Järvinen P., Isola J. Amplification of HER-2 neu and topoisomerase II α in primary and metastatic breast cancer. Cancer Res. 2001, 61:5345-5348.
10. Niehans G.A., Singleton T.P., Dykoski D., Kiang D.T. Stability of HER-2 expression over time and multiple metastatic sites. J. Natl. Cancer Inst. 1993, 85:1230-1235.
11. Edgerton S.M., Merkel D., Moore D., Thor A.D. CerB-2 (HER-2) and breast cancer progression. Appl. Imm. Mol. Morph. 2003, 11:214-221.
12. Hoehn J.L., Plotka E.D., Dickson K.B. Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann. Surg. 1979, 190:69-71.
13. Kamby C., Rasmussen B.B., Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br. J. Cancer 1989, 60:252-257.
14. Butler J.A., Trezona T., Vargas H., State D. Value of measuring hormone receptor levels of regional metastatic carcinoma of the breast. Arch. Surg. 1989, 124:1131-1134.
15. Andersen J., Poulsen H.S. Relationship between estrogen receptor status in the primary tumour and its regional and distant metastases. An immunohistochemical study in human breast cancer. Acta Oncol. 1988, 27:761-765.
16. Needergaard L., Haerslev T., Jacobsen G.K. Immunohistochemical study of oestrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS 1995, 103:20-24.
17. Iguchi C., Nio Y., Itakura M. Heterogenic expression of estrogen receptor between the primary tumour and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome. J. Surg. Oncol. 2003, 83:85-93.
18. Zheng W., Lu J.L., Zheng J., Hu F., Ni C. Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression. Steroids 2001, 66:905-910.
19. Leidenius M.H., Vironen J.H., Riihelä M.S., Krogerus L.A., Toivonen T.S., von Smitten K.A. The prevalence of non-sentinel node metastases in breast cancer histologic subtypes. Am. J. Surg. 2002, 84:492-498.
20. Leikola J.P., Toivonen T., Krogerus L.A., von Smitten K.A.J., Leidenius M.H.K. Rapid immunohistochemistry enhances the intraoperative diagnosis of sentinel lymph node metastases in invasive lobular breast carcinoma. Cancer 2005, 104:14-19.
21. Tanner M., Gancberg D., Di Leo A., et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 2000, 157:1467-1472.
22. Hanna W.M., Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER-2 testing algorithm. Mod. Pathol. 2006, 19:481-487.
23. Allred D.C., Clark G.M., Molina R., et al. Overexpression of HER-2 and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 1992, 23:974-979.
24. Tsuda H., Hirodashi S. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erb B2-expression patterns in both the non-invasive and invasive portions. Pathol. Int. 1998, 58:518-525.
25. Simon R., Nocito A., Huebscher T., et al. Patterns of HER-2/ neu amplification and overexpression in primary and metastatic breast cancer. J. Nat. Cancer Inst. 2001, 93:1141-1146.
26. Tsutsui S., Ohno S., Murakami S., Kataoka A., Kinoshita J., Hachitanda Y. EGFR, c-erb B2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Eur. J. Surg. Oncol. 2002, 28:383-387.
27. Xu R., Perle M.A., Inghirami G., Chan W., Delgado Y., Feiner H. Amplification of HER-2/neu gene in HER-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod. Pathol. 2002, 15:116-124.
28. Regitnig P., Schippinger W., Lindbauer M., Samonigg H., Lax S.F. Change of HER-2-status in a subset of distant metastases from breast carcinomas. J. Pathol. 2004, 203:918-926.
29. Carlsson J., Nordgren H., Sjöström J., et al. HER-2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br. J. Cancer 2004, 90:2344-2348.
30. Tapia C., Savic S., Wagner U., et al. HER-2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res. 2007, 9:R31.
31. Charpin C., Martin P.M., De Victor B., Lavaut M.N., Habib M.C., Andrac L., Toga M. Multiparametric study (SAMBA 2000) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas: analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran coated charcoal assays and morphological data. J. Cancer Res. 1988, 48:1578-1586.
32. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. 2004, 101:9393-9398.
33. Diaz L.K., Sneige N. Estrogen receptor analysis for breast cancer. Current issues and keys to increasing testing accuracy. Adv. Anat. Pathol. 2005, 12:10-19.
34. Rhodes A., Jasani B., Balaton A.J., Barens D.M., Miller K.D. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J. Clin. Pathol. 2000, 53:688-696.
35. Douglas-Jones A.G., Collett N., Morgan J.M., Basani B. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J. Clin. Pathol. 2001, 54:951-955.
36. Moriki T., Takahashi T., Shousuke U., Mitani M., Ichien M. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn. Cytopathol. 2004, 30:251-256.
37. Wolff A.C., Hammond E.H., Schwartz J.N., Hagerty K.L., Allred C., et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
38. Glöckner S., Buurman H., Kleeberger W., Lehmann U., Kreipe H. Marked intratumoral heterogeneity of c-myc and cyclin D1 but not of c-erb B2 amplification in breast cancer. Lab. Invest. 2002, 82:1419-1426.
39. Hanna W., Nofech-Mozes S., Kahn H.J. Intratumoral heterogeneity of HER 2/neu in breast cancer - a rare event. The Breast J. 2007, 13:122-129.
40. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J. Comparison of FISH and IHC for the evaluation of HER-2/neu in breast cancer. J. Clin. Oncol. 1999, 17:1974-1982.
41. Kallioniemi O.P., Kallioniemi A., Kurisu W., Thor A., Chen L.C., Smith H.S., Waldman F.M., Pinkel D., Gray J.W. ERBB2 amplification in breast cancer analysed by fluorescence in situ hybridization. Proc. Natl. Acad. Sci. USA 1992, 89:5321-5325.
42. Ciocca D.R., Fujimura F.K., Tandon A.K., Clark G.M., Mark C., Lee-Chen G.J., Pounds G.W., Vendely P., Owens M.A., Pandian M.R. Correlation of Her-2 neu amplification with expression and with other prognostic factors in 1103 breast cancers. J. Natl. Cancer Inst. 1992, 84:1279-1282.
43. Vera-Roman J.M., Rubio-Martinez L.A. Comparative Assays for the Her-2/neu Oncogene status in breast cancer. Arch. Pathol. Lab. Med. 2004, 128:627-633.
44. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Duane E.K., Levin W.J., Stuart S.G., Udove J., Ullrich A., Press M.F. Studies on HER-2/neu Proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
45. van Deurzen C.H.M., Bult P., de Boer M., Koelemij R., van Hillegersberg R., Tjan-Heijnen V.C.G., Hobbelink M.G.G., de Bruin P., van Diest P.J. Morphometry of isolated tumour cells in breast cancer sentinel lymph nodes: metastases or displacement?. Am. J. Surg. Pathol. 2009, 33:106-110.